Featured Publication Advancing Shared Goals Click here to read the full reportResearch Papers Patient and provider costs of the new BPaL regimen for drug-resistant tuberculosis treatment in South Africa: A cost-effectiveness analysis Savings from the introduction of BPaL and BPaLM regimens at the country level Experiences in the introduction of bedaquiline pretomanid linezolid for drug-resistant tuberculosis in KyrgyzstanFor the PressPress Contact:Jess Wiggsp | +1 646 616 8613e | jessica.wiggs@tballiance.org View the 2023 Annual Report
